Form 8-K - Current report:
SEC Accession No. 0001213900-25-064456
Filing Date
2025-07-16
Accepted
2025-07-16 07:20:57
Documents
14
Period of Report
2025-07-15
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0249097-8k_allarity.htm   iXBRL 8-K 26235
2 PRESS RELEASE, DATED JULY 15, 2025 ea024909701ex99-1_allarity.htm EX-99.1 16838
3 GRAPHIC ex99-1_001.jpg GRAPHIC 9102
  Complete submission text file 0001213900-25-064456.txt   226259

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE allr-20250715.xsd EX-101.SCH 3014
5 XBRL LABEL FILE allr-20250715_lab.xml EX-101.LAB 34239
6 XBRL PRESENTATION FILE allr-20250715_pre.xml EX-101.PRE 22358
16 EXTRACTED XBRL INSTANCE DOCUMENT ea0249097-8k_allarity_htm.xml XML 3685
Mailing Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108
Business Address 24 SCHOOL ST., 2ND FLOOR BOSTON MA 02108 401-426-4664
Allarity Therapeutics, Inc. (Filer) CIK: 0001860657 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41160 | Film No.: 251126148
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)